Form 4: Edwards Lifesciences Executive Stock Transaction

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, executed stock option exercises and sales under a 10b5-1 plan.

Summary

• Daniel J. Lippis, CVP of TAVR, exercised stock options for 2,038 shares at a strike price of $59.2567.
• The reporting person sold a total of 2,038 shares through multiple transactions between May 1, 2026, and May 4, 2026.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2025.
• Following these transactions, the reporting person holds 33,681.9103 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive compensation liquidity events.

Positives

• Transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.

Negatives

• The executive reduced their direct beneficial ownership of company stock through these sales.

Risks

• Market volatility affecting the weighted average sale prices of shares.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is standard corporate practice and generally does not signal a lack of confidence in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice among S&P 500 executives to avoid potential insider trading allegations.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were pre-planned and executed within a defined trading window.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Stock Options, TAVR